Search

Your search keyword '"Ris, Hans-Beat"' showing total 468 results
Start Over Author "Ris, Hans-Beat"
468 results on '"Ris, Hans-Beat"'

3. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

Author

Früh, Martin, Betticher, Daniel C., Stupp, Roger, Xyrafas, Alexandros, Peters, Solange, Ris, Hans Beat, Mirimanoff, Rene Olivier, Ochsenbein, Adrian F., Schmid, Ralph, Matzinger, Oscar, Stahel, Rolf A., Weder, Walter, Guckenberger, Matthias, Rothschild, Sacha I., Lardinois, Didier, Mach, Nicholas, Mark, Michael, Gautschi, Oliver, Thierstein, Sandra, Biaggi Rudolf, Christine, and Pless, Miklos

Published
2019
Full Text
View/download PDF

5. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Author

Pless, Miklos, Stupp, Roger, Ris, Hans-Beat, Stahel, Rolf A, Weder, Walter, Thierstein, Sandra, Gerard, Marie-Aline, Xyrafas, Alexandros, Früh, Martin, Cathomas, Richard, Zippelius, Alfred, Roth, Arnaud, Bijelovic, Milorad, Ochsenbein, Adrian, Meier, Urs R, Mamot, Christoph, Rauch, Daniel, Gautschi, Oliver, Betticher, Daniel C, Mirimanoff, René-Olivier, and Peters, Solange

Published
2015
Full Text
View/download PDF

21. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial

Author

Stupp, Roger, Mayer, Michael, Kann, Roger, Weder, Walter, Zouhair, Abderahim, Betticher, Daniel C, Roth, Arnaud D, Stahel, Rolf A, Majno, Sabine Balmer, Peters, Solange, Jost, Lorenz, Furrer, Markus, Thierstein, Sandra, Schmid, Ralph A, Hsu-Schmitz, Shu-Fang, Mirimanoff, René-Olivier, Ris, Hans-Beat, and Pless, Miklos

Published
2009
Full Text
View/download PDF

24. Incidence and Risk Factors of Abdominal Complications After Lung Transplantation

Author

Grass, Fabian, Schäfer, Markus, Cristaudi, Alessandra, Berutto, Carine, Aubert, John-David, Gonzalez, Michel, Demartines, Nicolas, Ris, Hans-Beat, Soccal, Paola, Krueger, Thorsten, Grass, Fabian, Schäfer, Markus, Cristaudi, Alessandra, Berutto, Carine, Aubert, John-David, Gonzalez, Michel, Demartines, Nicolas, Ris, Hans-Beat, Soccal, Paola, and Krueger, Thorsten

Abstract

Background: Due to the underlying diseases and the need for immunosuppression, patients after lung transplantation are particularly at risk for gastrointestinal (GI) complications that may negatively influence long-term outcome. The present study assessed the incidences and impact of GI complications after lung transplantation and aimed to identify risk factors. Methods: Retrospective analysis of all 227 consecutively performed single- and double-lung transplantations at the University hospitals of Lausanne and Geneva was performed between January 1993 and December 2010. Logistic regressions were used to test the effect of potentially influencing variables on the binary outcomes overall, severe, and surgery-requiring complications, followed by a multiple logistic regression model. Results: Final analysis included 205 patients for the purpose of the present study, and 22 patients were excluded due to re-transplantation, multiorgan transplantation, or incomplete datasets. GI complications were observed in 127 patients (62%). Gastro-esophageal reflux disease was the most commonly observed complication (22.9%), followed by inflammatory or infectious colitis (20.5%) and gastroparesis (10.7%). Major GI complications (Dindo/Clavien III-V) were observed in 83 (40.5%) patients and were fatal in 4 patients (2.0%). Multivariate analysis identified double-lung transplantation (p=0.012) and early (1993-1998) transplantation period (p=0.008) as independent risk factors for developing major GI complications. Forty-three (21%) patients required surgery such as colectomy, cholecystectomy, and fundoplication in 6.8, 6.3, and 3.9% of the patients, respectively. Multivariate analysis identified Charlson comorbidity index of ≥3 as an independent risk factor for developing GI complications requiring surgery (p=0.015). Conclusion: GI complications after lung transplantation are common. Outcome was rather encouraging in the setting of our transplant center.

Published
2021

25. Experimental ex vivo lung perfusion with sevoflurane: effects on damaged donor lung grafts

Author

Wang, Xingyu, Parapanov, Roumen, Francioli, Cyril, Perentes, Jean Yannis, Letovanec, Igor, Gonzalez, Michel, Kern, Christian, Ris, Hans-Beat, Piquilloud, Lise, Marcucci, Carlo, Krueger, Thorsten, Liaudet, Lucas, Gronchi, Fabrizio, Wang, Xingyu, Parapanov, Roumen, Francioli, Cyril, Perentes, Jean Yannis, Letovanec, Igor, Gonzalez, Michel, Kern, Christian, Ris, Hans-Beat, Piquilloud, Lise, Marcucci, Carlo, Krueger, Thorsten, Liaudet, Lucas, and Gronchi, Fabrizio

Abstract

OBJECTIVES Volatile anaesthetics can provide significant protection against reperfusion injury in various experimental settings. The aim of this study was to assess the potential of sevoflurane treatment, the most commonly used volatile anaesthetic in modern anaesthesia, in rat lungs donated after circulatory death and reconditioned in an ex vivo lung perfusion (EVLP) system. METHODS Fifteen rats were sacrificed and divided into 3 groups. In the control and sevoflurane groups, the heart-lung blocks were exposed to 1 h of warm ischaemia and 2 h of cold ischaemia and were mounted on an EVLP circuit for 3 h, in the absence or in the presence of 2% sevoflurane. In the baseline group, heart-lung blocks were harvested immediately after euthanasia. Physiological data, lung nitro-oxidative stress, lactate dehydrogenase (LDH), expression of cytokines, oedema and histopathological findings were assessed during or post-EVLP. RESULTS The sevoflurane group showed significantly reduced LDH (8.82 ± 3.58 arbitrary unit vs 3.80 ± 3.02 arbitrary unit, P = 0.03), protein carbonyl (1.17 ± 0.44 nmol⋅mg−1 vs 0.55 ± 0.11 nmol⋅mg−1, P = 0.006), 3-nitrotyrosine (197.44 ± 18.47 pg⋅mg−1 vs 151.05 ± 23.54 pg⋅mg−1, P = 0.004), cytokine-induced neutrophil chemoattractant factor 1 (1.17 ± 0.32 ng⋅mg−1 vs 0.66 ± 0.28 ng⋅mg−1, P = 0.03) and tumour necrosis factor alpha (1.50 ± 0.59 vs 0.59 ± 0.38 ng⋅mg−1, P = 0.02) when compared with the control group. In addition, sevoflurane lungs gained significantly less weight (0.72 ± 0.09 g vs 0.72 ± 0.09 g, P = 0.044), had less perivascular oedema (0.58 ± 0.09 vs 0.47 ± 0.07, P = 0.036), and improved static pulmonary compliance (+0.215 ml⋅cmH2O−1, P = 0.003) and peak airways pressure (-1.33 cmH2O, P = 0.04) but similar oxygenation capacity (+1.61 mmHg, P = 0.77) and pulmonary vascular resistances (+0.078 mmHg⋅min⋅ml−1, P = 0.15) when compared with the control group. CONCLUSIONS These findings suggest that the potential of sevoflurane in protecting t

Published
2021

37. Acute limb ischaemia

Author

Nachbur, Bernard, primary, Baumgartner, Iris, additional, Do, Do, additional, Mahler, Felix, additional, and Ris, Hans-Beat, additional

Published
2005
Full Text
View/download PDF

47. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Author

Betticher, Daniel C., Schmitz, Shu-Fang Hsu, Tötsch, Martin, Hansen, Eva, Joss, Christine, von Briel, Christian, Schmid, Ralph A., Pless, Miklos, Habicht, James, Roth, Arnaud D., Spiliopoulos, Anastase, Stahel, Rolf, Weder, Walter, Stupp, Roger, Egli, Fritz, Furrer, Markus, Honegger, Hanspeter, Wernli, Martin, Cerny, Thomas, and Ris, Hans-Beat

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results